Clinical Trial

Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

Study acronym: LEAF-01
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and safety of lenvatinib plus tislelizumab versus lenvatinib alone for patients with advanced hepatocellular carcinoma (HCC) who have progressed on prior systemic treatment with Anti-PD1/PD-L1 plus bevacizumab combination.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-24.
Status change: Not Yet Recruiting → Recruiting 2025-07-01
Trial Details
NCT Number NCT07047586
Lead Sponsor Fudan University
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 146 participants
Start Date 2025-07-02
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-03